SARS-CoV-2 pneumonia
[대역어] SARS-COV-2 폐렴
[용어속성] Disease
[용어속성] Disease
High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial
COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
active cancer
acute respiratory distress
acute respiratory distress syndrome
Adult patients
advance directives
Advanced cancer
age
alpha error
anticipated
approved
ARDS
assessment
assigned
bilateral pulmonary infiltrates
Blinding
block
breast-feeding
Buenos Aires
capture
cardiac disease
CEMIC
clinical
clinical trial
code
Complete
concealed
Confirmed
COVID-19
COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids
delirium
develop
Dexamethasone
diagnosis of SARS-CoV-2
directive
discharge
disease
dissemination
do not resuscitate
dose
Effectiveness
element
End-Expiratory Pressure
evaluate
exclusion criteria
Expiratory Pressure
explained
failure
followed by
Frequency
glucocorticoid
Glucocorticoids
group
hemodynamic
High dose
HIV infection
hypoxemic
Hypoxemic respiratory failure
ICU
Immunosuppression
Immunosuppressive agents
include
inclusion criteria
Infection
Informed consent
intensive care unit
International
legal guardian
Length
less
Life expectancy
local Ethics Committee
mechanical ventilation
Mortality
multicenter
muscle weakness
Nosocomial infection
Nosocomial infections
number
objective
open
open label
open trial
other disease
other diseases
outcome
Palliative care
PaO
parallel group
participant
Participation
Patient
Patient care
platform
Pneumonia
Positive end-expiratory pressure
power
power of 80%
Prednisone
pressure
Prone position
protocol
R language
random
randomised
randomised controlled trial
randomization
Randomized
randomized clinical trial
receive
recruitment
Registered
renal
renal disease
respiratory
respiratory distress
Respiratory distress syndrome
Respiratory failure
resuscitate order
RT-PCR
Sample size
SARS-COV-2 infection
SARS-CoV-2 pneumonia
secondary
Secondary outcomes
secondary to
sequence
Sequential Organ Failure Assessment
severe immunosuppression
SOFA
Standard deviation
status
Stratified randomization
Study protocol
subject
Support
syndrome
table
terminal
Terminal disease
title
Treatment
treatment groups
Trial
Trial registration
two-tailed alpha error
Variation
ventilator
ventilator-free day
Ventilator-free days
ventilatory
Version
viral shedding
weakness
website
women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter
A prediction model of outcome of SARS-CoV-2 pneumonia based on laboratory findings
Article
[키워드] acute respiratory syndrome
Algorithm
coronavirus
death
discharged patients
feasible
feature
fibrinogen degradation products
indirect bilirubin
Infectious diseases
Laboratory
laboratory feature
Laboratory features
logistic regression model
Myoglobin
non-survivor
operator
outcome
patients with SARS-CoV-2
Pneumonia
Prognosis
receptor
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 pneumonia
selected
sensitivity
Seven
specificity
urea
viral infection
were used
White blood cell
[DOI] 10.1038/s41598-020-71114-7 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-020-71114-7 PMC 바로가기 [Article Type] Article
Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 24 hour
absolute reduction
Administered
administration
AIFA
airway
allocation sequence
Alpha
Anticoagulant
anticoagulant therapy
Anticoagulant treatment
approval
Arm
Aspergillus
assigned
assumption
average
bleeding
bleeding event
blinded
Block randomisation
block size
BMI
Brain
Breastfeeding
Candida
checked
childbearing age
chronic
clinical
clinical condition
clinically
combined use
conjunctival
contributed
corpus
Corticosteroid
COVID-19
criteria
Critical
Critically ill
cytomegalovirus
D-dimer level
death
defined
Delay
detect
diagnostic
discharge
dissemination
dosage
drug
dysfunction
effective
element
eligible patient
enoxaparin
enrolled
EudraCT
exclusion criteria
expected
hematemesis
hematoma
heparin-induced thrombocytopenia
Herpe
high risk
High-dose
history
hospital
hospital discharge
Hypothesis
ICU
ICU free day
ICU Patients
impairing
Inclusion
inclusion criteria
indicated
Infection
initial
Inpatient
intensive care unit
interval
Intervention
Intra-articular
intramuscular
intravenously
invasive
Invasive mechanical ventilation
investigator
Italian
limit
LMWH
low molecular weight
low-molecular weight heparin
macroscopic
major bleeding
mechanical ventilation
medical intervention
Methylprednisolone
Mortality
mortality rate
Myocardial
Non-invasive
non-invasive ventilation
number
objective
occur
ophthalmic
organ dysfunction
PaO
parallel group
participant
Patient
performed
Pharyngeal swab
Pneumonia
positive
positive pressure
pregnancy test
Presence
Prophylactic
prophylactic dose
Prophylaxis
protocol
random
randomisation
randomised
randomised controlled trial
randomization
Randomized
Randomized controlled trial
Randomly
Ratio
receive
recent
recruited
recruitment
Rectal Bleeding
red blood cell
reduce
reducing
Registered
required
risk of death
Safety
Sample size
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 pneumonia
secondary
secure
severe disease
sick
significantly
sodium
status
steroid
stratified
stroke
study drug
Study protocol
subcutaneously
surgical
syndrome
therapeutic
therapeutic doses
therapy
Treatment
treatment group
unfractionated heparin
Venous Thromboembolism
ventilated patient
Ventilation
website
Weighting
Withdrawal
women
[DOI] 10.1186/s13063-020-04645-z PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04645-z PMC 바로가기 [Article Type] Letter
Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia
Review
[키워드] acute respiratory distress
acute respiratory syndrome
affecting
anti-inflammatory effect
ARDS
article
Biomarker
carried
Cell
characteristic
Combination
coronavirus
country
cytokines trigger
edema
effective antiviral treatment
Efficacy
Exosome
Exosomes
function
Health
induce
Inflammation
Inflammatory cytokines
lung
management
Mesenchymal stem cells
new virus
outbreak
Potential
pulmonary fibrosis
Result
SARS-CoV-2
SARS-CoV-2 pneumonia
SARS-CoV-2 virus infection
searched
secretion
selected
stem cells
syndrome
the patient
therapeutic
tissue regeneration
Treatment
Vaccine
virus pneumonia
[DOI] 10.1186/s13287-020-01866-6 PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s13287-020-01866-6 PMC 바로가기 [Article Type] Review
Neurological Manifestations of Severe SARS-CoV-2 Infection: Potential Mechanisms and Implications of Individualized Mechanical Ventilation Settings
Neurology
[키워드] 2019-nCoV
addition
affected
Brain
caused
change
complex interaction
coronavirus
Coronavirus disease 2019
COVID-19
Critically ill patient
distress
dry cough
endothelial cell damage
exacerbating
fatigue
Fever
Hyperinflammatory
Impact
impairment
include
Inflammatory response
interactions
lung
manifestation
Mechanical
mechanical ventilation
nervous system
neurological
neurological manifestation
neurological manifestations
neurotropism
Novel coronavirus
outbreak
outcomes
pandemic
pathogenic mechanism
physiological
Potential
reported
Respiratory Support
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 pneumonia
setting
Spread
Stress
Typical
ventilatory strategy
Wuhan, China
[DOI] 10.3389/fneur.2020.00845 PMC 바로가기 [Article Type] Neurology
[DOI] 10.3389/fneur.2020.00845 PMC 바로가기 [Article Type] Neurology
Breastfed 13 month-old infant of a mother with COVID-19 pneumonia: a case report
Case Report
[키워드] antibody
breast milk
Breastfeeding
Case report
China
COVID-19
COVID-19 pneumonia
diagnosed
Diagnosis
Evidence
Guidance
IgM and IgG
Infants
mother
nasopharyngeal
NP swab
outcome
Pneumonia
protective effect
reported
Safe
SARS-CoV-2
SARS-CoV-2 nucleic acid
SARS-CoV-2 pneumonia
serum
Support
Swab
Transmission
Treatment
was determined
were assessed
with COVID-19
[DOI] 10.1186/s13006-020-00305-9 PMC 바로가기 [Article Type] Case Report
[DOI] 10.1186/s13006-020-00305-9 PMC 바로가기 [Article Type] Case Report
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Research
[키워드] acute respiratory syndrome
Bronchoalveolar lavage fluid
cell-mediated response
Cellular immune response
ChAdOx1 nCoV-19
ChAdOx1 nCoV-19 against
Controlled clinical trial
coronavirus
coronavirus disease
COVID-19
COVID-19 disease
Cytokines
demonstrated
disease
Efficacy
ENCODE
Evidence
expression
humans
humoral
IgG
immunogenic
Lower respiratory tract
macaques
mice
nasal
no difference
PCR-positive
Pneumonia
Prevent
profile
Randomized
reduced
regimen
responsible
rhesus macaque
rhesus macaques
robust
SARS-CoV-2
SARS-CoV-2 pneumonia
significantly
symptomatic
T helper cell
T helper cells
the spike protein
tissue
Vaccine
viral challenge
Viral load
[DOI] 10.1038/s41586-020-2608-y [Article Type] Research
[DOI] 10.1038/s41586-020-2608-y [Article Type] Research
More than Just Pneumonia: Acute Pulmonary Embolism in Two Middle-Aged Patients with COVID-19
Case Report
[키워드] acting
age
anticoagulation
clinician
Complication
coronavirus disease
Course
diagnosed
discharged
distress
Embolism
hospital
hypercoagulable
increasingly
infected patients
Inflammatory response
management
mechanism
MONITOR
Patient
patients
predominant
prothrombotic
pulmonary
remained
report
reported
respiratory compromise
risk factor
SARS-CoV-2 pneumonia
severe pneumonia
Thromboembolic event
Venous Thromboembolism
virus
with COVID-19
[DOI] 10.1155/2020/4812036 PMC 바로가기 [Article Type] Case Report
[DOI] 10.1155/2020/4812036 PMC 바로가기 [Article Type] Case Report
Quantitative lung lesion features and temporal changes on chest CT in patients with common and severe SARS-CoV-2 pneumonia
Research Article
[키워드] acute respiratory syndrome
Algorithms
analyzed
automatically
calculated
change
Chest computed tomography
Chest CT
consolidation
coronavirus
decrease
diagnosed
Diagnostic Criteria
Evolution
exhibited
feature
ground-glass opacity
groups
increase in
initial symptom
initial symptoms
lung
lung lesion
Lungs
Patient
patients
peaked
percentage
Pneumonia
Quantitative
Record
SARS-CoV-2
SARS-CoV-2 pneumonia
severe group
severe pneumonia
severe SARS-CoV-2
significantly
Stage
stage 2
subsequent
the patient
Volume
[DOI] 10.1371/journal.pone.0236858 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0236858 PMC 바로가기 [Article Type] Research Article